Figures & data
Figure 1 Concept of synthetic lethality explained with PARP inhibitors in the setting of BRCA mutation.
Abbreviations: DSB, double-stranded break; HRD, homologous recombination deficient; PARP poly-adenosine diphosphate ribose polymerase; SSB, single-stranded break.
Figure 2 Study 10 design.
Abbreviations: g/sBRCAm, germline/somatic BRCA mutation; MTD, maximum tolerated dose; PARP, poly-adenosine diphosphate ribose polymerase; PARPi, PARP inhibitor; RECIST, response evaluation criteria in solid tumors; RP2D, recommended phase II dose.
Figure 3 ARIEL2 study design.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PARP, poly-adenosine diphosphate ribose polymerase; PFS, progression-free survival; RECIST, response evaluation criteria in solid tumors.
Figure 4 ARIEL3 study design.
Abbreviations: CR, complete response; PR, partial response; GCIG, Gynecologic Cancer Intergroup; R, randomization; RECIST, response evaluation criteria in solid tumors.
Figure 5 ARIEL3 efficacy analysis nested cohorts.
Abbreviations: gBRCAmut, germline BRCA mutation; HRD, homologous recombination deficiency; ind, indeterminate; ITT, intention-to-treat; R, randomization; sBRCAm, somatic BRCA mutation; LOH, loss-of-heterozygosity.
Table 1 Current rucaparib trials in ovarian cancer and other disease types
Table 2 Examples of other PARP inhibitors under phase III investigation in the US according to www.ClinicalTrials.gov